World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
45
Citations
9682
World Ranking
4681
National Ranking
2110

Marc Gurwith publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Marc Gurwith sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 115 publications — 6th percentile

6% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Marc Gurwith D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Marc Gurwith sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 45 D-Index — 6th percentile

6% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Marc Gurwith is affiliated with Michigan State University in the United States and has contributed extensively to research in the field of medicine. Their publications primarily focus on infectious diseases, with additional work in health, genetics, epidemiology, and molecular biology.

The scientist's research concentrates on major topics including:

  • SARS-CoV-2 and COVID-19 Research
  • Viral Infections and Outbreaks Research
  • Vaccine Coverage and Hesitancy
  • Virus-based Gene Therapy Research
  • Viral Gastroenteritis Research and Epidemiology
  • Bacillus and Francisella Bacterial Research
  • Viral Infections and Immunology Research

Marc Gurwith has a notable record of publications in several venues, including:

  • Vaccine
  • Journal of Clinical Investigation
  • UNC Libraries
  • Zenodo (CERN European Organization for Nuclear Research)
  • SSRN Electronic Journal

The scientist has collaborated frequently with other researchers. Some of the frequent co-authors include:

  • Robert T. Chen
  • Emily Smith
  • Denny Kim
  • James S. Robertson
  • Richard Condit

Selected recent papers authored by Marc Gurwith include:

  • "Vaccine-associated enhanced disease: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data" (2021), published in Vaccine
  • "Vaccines based on replication incompetent Ad26 viral vectors: Standardized template with key considerations for a risk/benefit assessment" (2020), published in Vaccine
  • "The critical role of background rates of possible adverse events in the assessment of COVID-19 vaccine safety" (2021), published in Vaccine
  • "A replication-competent adenovirus-vectored influenza vaccine induces durable systemic and mucosal immunity" (2021), published in Journal of Clinical Investigation
  • "Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: Standardized template with key considerations for a risk/benefit assessment" (2022), published in Vaccine

Best Publications

  • Randomized, Double‐Blind, Placebo‐Controlled Efficacy Trial of a Bivalent Recombinant Glycoprotein 120 HIV‐1 Vaccine among Injection Drug Users in Bangkok, Thailand

    Punnee Pitisuttithum;Peter Gilbert;Marc Gurwith;William Heyward

  • Correlation between Immunologic Responses to a Recombinant Glycoprotein 120 Vaccine and Incidence of HIV-1 Infection in a Phase 3 HIV-1 Preventive Vaccine Trial

    Peter B. Gilbert;Michael L. Peterson;Dean Follmann;Michael G. Hudgens

  • A Double-Blind, Randomized, Controlled Trial of Amphotericin B Colloidal Dispersion versus Amphotericin B for Treatment of Invasive Aspergillosis in Immunocompromised Patients

    Raleigh Bowden;Pranatharthi Chandrasekar;Mary H. White;Xin Li

  • A Prospective Study of Rotavirus Infection in Infants and Young Children

    Marc Gurwith;Marc Gurwith;Marc Gurwith;Wanda Wenman;Wanda Wenman;Wanda Wenman;Dorothy Hinde;Dorothy Hinde;Dorothy Hinde;Sheila Feltham;Sheila Feltham;Sheila Feltham

  • Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled, phase 1 study

    Marc Gurwith;Michael Lock;Eve M Taylor;Glenn Ishioka

  • Comparison of HIV type 1 incidence observed during longitudinal follow-up with incidence estimated by cross-sectional analysis using the BED capture enzyme immunoassay.

    J. Steven McDougal;Bharat S. Parekh;Michael L. Peterson;Bernard M. Branson

  • LC16m8: an attenuated smallpox vaccine.

    Julie Kenner;Fiona Cameron;Cyril Empig;David V. Jobes

  • Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus: Results of a multicenter randomized, double-blind, placebo-controlled trial

    Michelle A. Petri;Philip J. Mease;Joan T. Merrill;Robert G. Lahita

  • Single-dose Live Oral Cholera Vaccine CVD 103-HgR Protects Against Human Experimental Infection With Vibrio cholerae O1 El Tor

    Wilbur H. Chen;Mitchell B. Cohen;Beth D. Kirkpatrick;Rebecca C. Brady

  • Magnitude and Breadth of a Nonprotective Neutralizing Antibody Response in an Efficacy Trial of a Candidate HIV-1 gp120 Vaccine

    Peter Gilbert;Maggie Wang;Terri Wrin;Chris Petropoulos

  • Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: A randomized, double-blinded, controlled, multicenter trial

    Geoffrey J. Gorse;Wendy Keitel;Harry Keyserling;David N. Taylor

  • Lack of Effect of Peroral Acyclovir for the Treatment of Acute Infectious Mononucleosis

    C. Van Der Horst;J. Joncas;G. Ahronheim;N. Gustafson

  • RISK FACTORS FOR URINARY TRACT INFECTION

    Robert S. Remis;Marc J. Gurwith;Dorothy Gurwith;Nancy T. Hargrett-Bean

  • Candidate HIV/AIDS vaccines: lessons learned from the World's first phase III efficacy trials.

    Donald P Francis;William L Heyward;Vladimir Popovic;Patti Orozco-Cronin

  • Gastroenteritis in children: a two-year review in Manitoba. I. Etiology.

    Marc J. Gurwith;Trevor W. Williams

  • Motivations for participating in an HIV vaccine efficacy trial.

    Grant Colfax;Susan Buchbinder;Goli Vamshidar;Connie Celum

  • Vaccine-associated enhanced disease: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data.

    Flor M. Munoz;Jakob P. Cramer;Cornelia L. Dekker;Matthew Z. Dudley

  • Safety and Immunogenicity of LC16m8, an Attenuated Smallpox Vaccine in Vaccinia-Naive Adults

    Jeffrey S. Kennedy;Marc Gurwith;Cornelia L. Dekker;Sharon E. Frey

  • Diarrhea among Infants and Young Children in Canada: A Longitudinal Study in Three Northern Communities

    M. Gurwith;W. Wenman;D. Gurwith;J. Brunton

  • HIV-1 Virologic and Immunologic Progression and Initiation of Antiretroviral Therapy among HIV-1–Infected Subjects in a Trial of the Efficacy of Recombinant Glycoprotein 120 Vaccine

    Peter B. Gilbert;Marta L. Ackers;Phillip W. Berman;Donald P. Francis

  • Age, race/ethnicity, and behavioral risk factors associated with per contact risk of HIV infection among men who have sex with men in the United States.

    Hyman M. Scott;Eric Vittinghoff;Risha Irvin;Darpun Sachdev

  • Vaccines based on replication incompetent Ad26 viral vectors: standardized template with key considerations for a risk/benefit assessment

    Jerome Custers;Denny Kim;Maarten Leyssen;Marc Gurwith

Frequent Co-Authors

Robert T. Chen
Robert T. Chen City Of Hope National Medical Center
Myron M. Levine
Myron M. Levine University of Maryland, Baltimore
Peter B. Gilbert
Peter B. Gilbert Fred Hutchinson Cancer Research Center
Jason B. Harris
Jason B. Harris Newcastle University
Jordan W. Tappero
Jordan W. Tappero Centers for Disease Control and Prevention
Richard N. Greenberg
Richard N. Greenberg University of Kentucky
Stephen B. Calderwood
Stephen B. Calderwood Massachusetts General Hospital
David C. Montefiori
David C. Montefiori Duke University
Edward T. Ryan
Edward T. Ryan Harvard University
Susan Buchbinder
Susan Buchbinder University of California, San Francisco

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students studying Immunology in the USA, exploring related online degrees can expand career opportunities in healthcare and medical research. Many students pursue nursing pathways, connecting their biological science background with clinical practice.

Accelerated programs offer a faster track for those looking to advance quickly. For instance, an accelerated NP program provides a fast route to becoming a Nurse Practitioner, blending advanced immunology knowledge with patient care.

For individuals without prior nursing experience, online options like online BSN programs for non nurses help bridge the gap efficiently, often accommodating working professionals.

If speed and accessibility are priorities, researching the accelerated nursing programs can reveal options with less competitive admission processes, allowing quicker entry into nursing careers.

Similarly, entry-level roles like Licensed Practical Nurses can be a starting point, and exploring easy admission LPN programs may help candidates find straightforward pathways into practical nursing.

These related degrees and programs expand the scope of immunology studies into hands-on healthcare roles, offering varied pathways to impact patient outcomes and research development.

Best Scientists Citing Marc Gurwith

Trending Scientists

Recently Published Articles